BTIG affirms Cidara Therapeutics, Inc. (Nasdaq: CDTX) at Buy with a price target of $24 following recent quarterly results and ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments FDA

Wedbush Reiterates Outperform on Cidara Therapeutics (CDTX) Following 2Q August 16, 2016 8:21 AM Needham & Company Reiterates Buy on Cidara Therapeutics (CDTX) Following 2Q Report August 15, 2016 8:19 AM Cidara Reports Second Quarter 2016 Financial Results and Provides Corporate UpdateAugust 11, 2016 4:12 PM Form 10-Q Cidara Therapeutics, For: Jun 30August 11, 2016 4:08 PM Form 8-K Cidara Therapeutics, For: Aug 11August 11, 2016 4:02 PM